Background: The clinical significance of combined malonic and methylmalonic
| INTRODUCTION
Combined malonic and methylmalonic aciduria due to ACSF3 deficiency, termed non-classical combined malonic and methylmalonic aciduria, or CMAMMA, has been reported in 21 patients to date. Its clinical significance remains controversial.
ACSF3 encodes a mitochondrial acyl-CoA synthetase with high specificity for malonate and methylmalonate, 1 essential for the intramitochondrial synthesis of malonylCoA, the starting point for mitochondrial de novo fatty acid synthesis. CMAMMA caused by ACSF3 deficiency is therefore entirely distinct from "classical" methylmalonic acidurias due to deficiency of methylmalonyl-CoA mutase or to deficient synthesis of its cofactor adenosylcobalamin. ACSF3 encodes a mitochondrial acyl-CoA synthetase with high specificity for malonate and methylmalonate, 1 essential for the intramitochondrial synthesis of malonyl-CoA, the starting point for mitochondrial de novo fatty acid synthesis. CMAMMA caused by ACSF3 deficiency is therefore entirely distinct from "classical" methylmalonic acidurias due to deficiency of methylmalonyl-CoA mutase or to deficient synthesis of its cofactor adenosylcobalamin. CMAMMA is also distinguishable from the other condition with increases of both malonic and methylmalonic acids: malonic aciduria due to deficiency of malonyl-CoA decarboxylase. The latter is a severe condition with frequent episodes of metabolic acidosis and hypoglycaemia, cardiomyopathy, neurodevelopmental abnormalities, seizures, renal dysplasia, and markedly high excretion of malonic acid (MA) [2] [3] [4] [5] with mildly elevated excretion of methylmalonic acid (MMA), [2] [3] [4] [5] possibly due to the inhibition of methylmalonyl-CoA mutase by malonyl-CoA. 4 The MMA/MA ratio is less than 1 in malonyl-CoA decarboxylase deficiency. 4 In contrast, in CMAMMA patients, MMA levels exceed those of MA. Mutations in ACSF3 were identified by exome sequencing in patients with combined MMA and MA elevations and negative molecular testing for malonic aciduria. 6, 7 The clinical significance of CMAMMA is not established to date. The initial three Quebec patients, 6 identified through the provincial population urine-based newborn screening (NBS) program, 8 were asymptomatic. The other 18 patients described to date 7,9-11 had a broad range of symptoms (see Suppl. Table 3 ) that brought them to medical attention. The Provincial Neonatal Urine Screening Program (at CHU Sherbrooke) uses urine-soaked filter paper collected by parents at 3 weeks of age to screen directly for elevated MMA and other metabolites. 8, 12, 13 As ACSF3-related CMAMMA does not cause accumulation of methylmalonylCoA, propionyl-CoA or malonyl-CoA, it is not associated with an abnormal acylcarnitine profile, 6, 7 and hence would not be detected using standard blood-based NBS methods.
The Quebec cohort of CMAMMA patients is thus unique in having been ascertained through newborn urine screening rather than through clinical investigation of symptoms and is therefore the only cohort in the world free of selection bias. The clinical significance of CMAMMA is not established to date. The initial three Quebec patients, 6 identified through the provincial population urine-based newborn screening (NBS) program, 8 were asymptomatic. The other 18 patients described to date 7,9-11 had a broad range of symptoms (see Suppl. Table 3 ) that brought them to medical attention. The Provincial Neonatal Urine Screening Program (at CHU Sherbrooke) uses urine-soaked filter paper collected by parents at 3 weeks of age to screen directly for elevated MMA and other metabolites. 8, 12, 13 As ACSF3-related CMAMMA does not cause accumulation of methylmalonyl-CoA, propionylCoA or malonyl-CoA, it is not associated with an abnormal acylcarnitine profile, 6, 7 and hence would not be detected using standard blood-based NBS methods. The Quebec cohort of CMAMMA patients is thus unique in having been ascertained through newborn urine screening rather than through clinical investigation of symptoms and is therefore the only cohort in the world free of selection bias. In order to further characterize CMAMMA clinically, biochemically, and molecularly, we performed a multicenter retrospective natural history study to identify all known Quebec patients with CMAMMA. The existence in Quebec of asymptomatic patients with normal outcomes despite persistent mild or moderate methylmalonic aciduria had long been recognized 13 and most CMAMMA patients were originally classified as having benign methylmalonic aciduria of unknown etiology. The diagnosis of CMAMMA was established recently after review of the organic acid profiles following the discovery of the biochemical profile of this condition. 6, 7 We contrast the Quebec cohort with the clinical descriptions of all previously reported CMAMMA patients (see Suppl. Table 3 for a summary of all reported cases).
| MATERIALS AND METHODS

| Patient and data collection
A retrospective medical record review was performed under a multi-institution REB-approved protocol (#MP-CUSM-10-131-PED). Questionnaires (Suppl. Table 1 ) were sent to metabolic clinicians at all four university hospital centers in the province of Quebec to characterize all known patients with CMAMMA. Clinicians reviewed the medical records and were not asked to perform additional evaluations for the study. Ascertainment was complete according to records of the two biochemical genetic laboratories responsible for organic acid analysis in the province.
| Data analysis
The completed questionnaires were analyzed using Microsoft Excel to compute median, minimum, and maximum values for MMA, MA, and MMA/MA ratios from organic acid profiles. Median values were used to minimize the influence of outliers. MMA results using a dedicated MMA assay and those from NBS samples (urine filter papers) were compiled separately. An exact binomial goodness-of-fit test 14 was used to assess whether the clinical signs or symptoms observed in our cohort were significantly overrepresented as compared to their prevalence in the general population.
| Organic acid profile analysis
This was done by gas chromatography-mass spectrometry (GC-MS) in biochemical genetics laboratories (at CHU Sherbrooke (CHUS) and CHU Ste-Justine) using similar methods, based on widely-used techniques. 15 
| Dedicated MMA assay
Also using GC-MS, MMA alone was quantitated by stable isotope dilution with a deuterated MMA internal standard.
| Population urine NBS
Urine eluted from filter papers was analyzed by thin-layer chromatography. 8 Eluates showing MMA elevations were subjected to quantitation by GC-MS (at CHUS). Results above 250 mmol MMA/mol creatinine were considered 'screen-positive' and the infant was referred to a university hospital center. Results between 200 and 250 mmol/mol were considered 'borderline' and prompted a request for a second sample.
| ACSF3 analysis
ACSF3 gene sequencing (all nine coding exons) was performed in certified molecular diagnostic laboratories as part of the clinical investigation of patients with a biochemical phenotype compatible with CMAMMA.
3 | RESULTS 
| Patient characteristics
| Method of ascertainment
All patients but one (96%) were diagnosed as a result of urine NBS, either directly (20/25, or 80%) or following the diagnosis of an older sibling (4/25, or 16%). MMA levels on NBS were available for 19/25 patients (76%) and the median was 460 mmol/mol creatinine (range 198-2416). Patient 20 was clinically ascertained after presenting at age 4 weeks with severe metabolic acidosis in the context of an episode of bloody diarrhea causing dehydration and hypovolemia. Metabolic evaluation including urine organic acid analysis was performed at that time. The acidosis resolved quickly with fluid resuscitation, and the subsequent course was benign. No sample for urinary newborn screening appears to have been submitted.
| Clinical manifestations
We found no specific or consistent pattern of clinical manifestations (Table 1) . Echocardiograms were performed for 8/25 (32%) of patients and were normal except for mild pulmonary valvular stenosis (patient 16) and mild left ventricular dilatation (patient 23) that resolved and did not require cardiology follow-up. Ophthalmologic examinations were performed in 10/25 patients (40%). They were normal except for one patient with congenital unilateral persistent hyperplastic primary vitreous (PHPV) causing glaucoma and cataract, one with bilateral dacryostenosis and one patient with latent nystagmus. Abdominal ultrasound was performed for 7/25 patients (28%) with normal results in 4. One showed unilateral grade 1-2 hydronephrosis with renal cysts, and two had mild and transient increased hepatic volume in infancy. ADHD attention deficit hyperactivity disorder, age age at the time of chart review, in years unless otherwise specified, Dx Mode of diagnosis, GERD gastro-oesophageal reflux disease, n/a not available, mo months, NBS diagnosed via urinary newborn screening, the MMA level in mmol/mol creatinine at newborn screening is given in parentheses if available, Pt patient, sib sibling, sx diagnosed via biochemical investigation performed because of clinical symptoms suggestive of an inborn error of metabolism, UTI urinary tract infection.
Apart from patient 20 described above, none had an acute metabolic event. Patient 16 had no metabolic acidosis despite being admitted to ICU for a severe bronchiolitis. Patient 19 had unexplained cycles of nocturnal vomiting beginning in adolescence; abdominal ultrasound, brain MRI and CT scan did not yield a diagnosis, and work-up during one episode showed no metabolic derangement.
Three patients (12%) were diagnosed with ADHD, similar to 11% reported in the pediatric population by the US Center of Disease Control and Prevention (www.cdc.gov) and in other publications. 16 One of these patients (4%) also had a specific learning disability (dysorthographia); this proportion is not significantly different from the population prevalence of 9.7% 17 (p = 0.51). Another patient had mild language and fine motor delays in early childhood, which corrected by school age. Five of 25 patients (20%) had various skin manifestations (Table 1) . Regarding gastrointestinal issues, one patient (4%) had bovine protein intolerance in infancy and another (4%) had gastro-oesophageal reflux disease requiring Nissen fundoplication. These observations are not significantly 
| Treatment
Ten of 25 patients (40%) received cobalamin at some point. Seven were treated with intramuscular hydroxocobalamin; in all cases, the treatment had no clinical or biochemical effect and was discontinued. Patient 14 had mild vitamin B12 deficiency as a breastfed infant (93 pmol/L, normal 148-722); the mother was vitamin B12 deficient. Patients 19 and 20 also developed mild dietary vitamin B12 deficiency. In all three cases, B12 levels normalized with oral cyanocobalamin supplementation, and this had no significant effect on MMA or MA levels. Overall, B12 levels were available for 22/25 patients and were otherwise normal. Plasma total homocysteine levels, available for 20/25, were all normal. Four patients received L-carnitine supplementation. Patient 20 received this continuously since her early diagnosis of metabolic acidosis in the context of diarrhea (see above). Two siblings (patients 10 and 11) received carnitine (50 mg/kg/day) from age 4 and 7, respectively, after a mildly increased esterified/free carnitine was observed; the treatment was discontinued at adolescence due to poor compliance. Patients 4 and 20 both received L-carnitine during pregnancy and intravenous dextrose during labor as precautionary measures.
Eleven patients (44%) were initially treated with mild protein restriction; for most, the restriction was lifted, relaxed, or the patients stopped themselves. At present, four patients are still following a mildly protein-restricted diet, and three others are counseled to avoid protein overload without tracking protein intake rigorously. Table 2 presents the median and ranges, for each patient, of the following parameters: plasma MMA (dedicated assay), urine MMA, urine MA, and urine MMA/MA ratio (all obtained from organic acid profile analysis), and specific quantification of urine MMA (dedicated assay).
| Biochemical data
As previously reported for CMAMMA, 6,7 the urine MMA/MA ratio was greater than 1 in each sample from every patient (overall median 10, overall range 2-97). Individual patient median MMA levels from urine organic acid profiles ranged from 107 to 1857 mmol/mol creatinine (overall median 429, reference range < 10). In plasma MMA assay, the range was 8-42 μmol/L (median 16, reference range < 0.4). Notably, there were no elevations of propionyl-CoA metabolites (3-hydroxypropionic acid, methylcitric acid) or tiglylglycine in the urine organic acid profiles, consistent with the known biochemical basis of CMAMMA.
All patients had at least one significantly elevated value for urine MA. The median for individual patients ranged from 9 to 280 mmol/mol creatinine (overall median 40, reference range < 5). Six patients also had at least one organic acid profile in which MA was reported as undetectable; however, all such results were from analyses performed over 13 years ago, and all patients had elevated urine MA in every analysis performed since then. This discrepancy likely reflects recent improvement in analysis, interpretation, and reporting of MA results, partly due to greater awareness that even mild elevations of MA can be significant. Older samples were not available for retesting; the "zero" (undetectable) MA values were therefore excluded from the statistical analysis.
Plasma organic acid profile analysis was performed in four patients: MMA was elevated in all, MA was slightly elevated in two, normal in one, and undetectable in the other (data not shown). Plasma acylcarnitine profiles were available for 13/25 patients (52%) and were essentially normal. Specifically, there were no elevations of C3 (propionyl), C3DC (malonyl) or C4DC (sum of methylmalonyl and succinyl) carnitines, and no reduction in free carnitine. Urine acylglycine profiles were analyzed for 16 patients, using a sensitive LC-MS/MS method 22 ; all were normal. Urine NMR studies were performed on samples from a few patients, by Wevers and colleagues. 23 The NMR spectra showed elevated MMA and MA, without revealing abnormalities of any other metabolites.
| Molecular data
As shown in Table 3 , ACSF3 sequencing or detection of familial mutations was performed in 19/25 patients (76%). If one assumes that siblings carry the same mutation, the number of patients for whom the causal mutations are known is 20/25 (80%). Parental studies were available for six patients and showed the expected segregation. All mutations were missense apart from a splice site mutation representing 2/50 alleles in our cohort (c.1239 + 2 T > G) and three frameshift mutations (c.1718delT, c.774_775del, and c.1446-1447delCA). All genotyped patients carried at least one missense allele. Excluding siblings, the most common mutations were c.1075G > A (p.E359K), representing 38.2% of alleles, and c.1672C > T (p.R558W), representing 20.6% of alleles. Similarly, all identified mutations were missense in the cohort described by Sloan et al. 7 except c.1567C > T (p.R523X), which represented 1/16 (6.25%) alleles. Their most common allele (second most common in our cohort), c.1672C > T (p.R558W), accounted for 31.5% of alleles, while c.1075G > A (p.E359K) (the most common in our cohort) was only observed once (6.25% of alleles). Novel mutations were seen (marked in bold in Table 3 and in Suppl. Table 3 ), but overall there was substantial overlap of ACSF3 mutations between studies (Suppl. investigations, but could only report on what had been done in the course of clinical follow-up. We therefore cannot exclude the possibility of undiagnosed subclinical complications. Even without full investigations, however, the absence of any consistent pattern of overt clinical symptoms despite follow-up for a total of 297.5 patient-years is reassuring. It suggests that CMAMMA is a benign condition, in our unbiased cohort, in the age range represented. The largely benign clinical course in our cohort stands in contrast to the symptomatic patients described.
7,9,10 By identifying patients through population-based newborn screening, our cohort uniquely eliminates selection bias and should more accurately reflect the evolution of CMAMMA. Conversely, all patients from outside Quebec were diagnosed with CMAMMA in the course of investigating various symptoms suggesting a possible metabolic disorder, with one individual ascertained from an exome database of patients with cardiovascular disease. 7 It is therefore possible that these symptoms were in fact unrelated to their CMAMMA. We cannot, however, completely exclude the possibility of CMAMMA being associated with the onset of clinical manifestations later in life as our oldest patient is 30 years old while 4/9 patients reported by Sloan et al. 7 were older. It is unlikely that specific mutations dictate the phenotype, considering the considerable overlap of ACSF3 mutations in all studies. Most of our patients were followed by metabolic teams, and many received at some point protein restriction, L-carnitine, and/or sick-day management. It might be suggested that our patients' course was benign due to pre-symptomatic management. Against this is the absence of symptoms despite great variation in management, and that treatment, if any, was discontinued years ago for most patients. Furthermore, our patients were treated on the presumption they had a mild form of classic methylmalonic aciduria. As the n/a not available, Pt patient, sib sibling.
biochemical basis and potential pathophysiology of CMAMMA are different, it cannot be assumed that the treatment was in fact appropriate or effective. Potential disease-causing mechanisms for CMAMMA would therefore include accumulation of upstream metabolites (MA and MMA), and impairment of mitochondrial fatty acid synthesis due to a lack of intramitochondrial malonylCoA. If we posit that ACSF3 deficiency is in fact a benign condition, it becomes necessary to account for the absence of negative effects mediated by these two mechanisms.
Accumulations of free MA and MMA were associated with neurotoxicity in vitro. 29 MA causes mitochondrial toxicity, 30, 31 being a reversible competitive inhibitor of succinate dehydrogenase (SDH), 31 and MMA inhibits the respiratory chain in hippocampal and striatal neurons. 32 Administration of MMA to rodents was associated with central nervous system 33, 34 and other organ toxicity. 35 Knock out (KO) of ACSF3 using CRISPR/Cas9 methods in human cells 36 showed defects in mitochondrial metabolism related to SDH inhibition by malonate. Although the concentrations of these metabolites in CMAMMA may be insufficient on their own to produce disease, their accumulation may prove to be a risk factor for multifactorial disease, or effects may become more apparent with age. Acsf3 null mice manifested neuromotor abnormalities that became apparent in adulthood. 37 Malonyl-CoA is the starting point for mitochondrial de novo fatty acid synthesis. ACSF3, a mitochondrial acylCoA synthetase with high specificity for malonate and methylmalonate, is required for intramitochondrial malonyl-CoA synthesis.
1 Malonyl-CoA is used to form octanoyl-ACP (an octanoyl moiety bound to acyl-carrier protein), the starting point for mitochondrial lipoic acid synthesis. Lipoylation of several mitochondrial proteins (pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, branched-chain ketoacid dehydrogenase, 2-oxoadipate dehydrogenase, and the glycine cleavage system) is essential to their function, and disorders of lipoic acid synthesis are associated with defects of mitochondrial energy metabolism. 38 ACSF3 knockdown by RNA interference did not cause a lipoylation defect in vitro. 1 The treated cells in this experiment maintained 37% of ACSF3 activity and 83% of normal octanoyl-ACP. It was speculated that this residual activity permitted adequate lipoic acid synthesis. However, defects in protein lipoylation were not detected in ACSF3 KO cells either. 36 Another role emerging for malonyl-CoA is post-translational malonylation of lysine residues in mitochondrial proteins. 36 Reduced protein malonylation was observed in ACSF3 KO cells, but the metabolic effects of this remains to be investigated. None of the patients in our cohort, or previously reported, 6 ,7,9-11 carry two mutations predicted a priori to be null. Although the residual enzyme activities of the corresponding mutant proteins have not been determined, it is possible that they retain enough activity for mitochondrial functions not to be significantly impacted. It is also plausible that there are alternative mechanisms for the intramitochondrial synthesis of malonyl-CoA. It was shown in rats that mitochondrial propionyl-CoA carboxylase is capable of converting acetyl-CoA to malonyl-CoA. 39 Hiltunen and colleagues 40 speculated about the existence of a malonyl-CoA transporter or mitochondrially targeted isoform of acetylCoA carboxylase. Recently, a mitochondrial isoform of cytosolic acetyl-coA carboxylase (ACC1) was, in fact, identified and shown to act in concert with ACSF3 to generate mitochondrial malonyl-CoA. 41 The frequency of CMAMMA, based on ACSF3 mutant allele frequency studies, was estimated at 1/30000, 7 implying that the condition is under-diagnosed, probably due to a lack of symptoms in most patients as well as inability to detect CMAMMA by NBS using blood acylcarnitine profiles. Even in Quebec, the observed birth incidence is significantly lower than would be predicted from allele frequencies. Several patients in our study had borderline initial screening results; there were likely others falling just below the cut-off. One sibling with CMAMMA had screening results below the cut-off, but was investigated further as a familial case. Furthermore, follow-up urine and plasma testing focused on MMA and mild elevations of MA were not reported. The diagnostic significance of mildly elevated MA was not obvious 13 prior to the identification of CMAMMA. In this era of 'MMA gene panels' and wholeexome sequencing, additional individuals may be identified without the characteristic biochemical pattern of combined excretion of MMA and MA.
In conclusion, we describe a cohort of 25 largely asymptomatic patients with ACSF3-associated CMAMMA, all but one diagnosed via population-based urine newborn screening. Our findings suggest that CMAMMA is a benign condition. Further study should further clarify its significance, or lack thereof; thus, simplifying management and avoiding for patients the burdens associated with an ambiguous diagnosis. 42 In practice, if CMAMMA is discovered in the course of evaluation of a symptomatic patient, the patient's symptoms should not be attributed to CMAMMA until other potential causes have been eliminated.
